In spite of a great success in breast cancer therapy, primary or acquired resistance to lapatinib still occurs, even when this medicament is used in combination with other commercially available anti-HER2 agents (e.g., trastuzumab) [11]. This evidence concerns the gene ERBB2 and breast carcinoma.